Patient Power 1

CAR T-Cell Therapy Results in Remission for Myeloma Patients

  Mar 03 2021 Tagged CAR-T, MM

In a study posted online by the New England Journal of Medicine, trial leaders report that almost 75% of the participants responded to the therapy, known as idecabtagene vicleucel (ide-cel), and one-third of them had a complete response, or disappearance of all signs of their cancer.

Visit website
Immunotherapy Web Featured Images 112

Patient education resource: Immunotherapy education session

View this resource for further information on what to do before starting immunotheraphy treatment.

Visit website
Cancer research institute 3

Cancer Immunotherapy: 2021 Research and Look Ahead - Webinar for patrients and c...

CRI Scientific Advisory Council Associate Director Dr. Kunle Odunsi discusses the future of cancer immunotherapy and what may lie aheads for the field.

Visit website
Patient Power2

Latest News on CAR T-Cell Therapy for Multiple Myeloma

  Jan 07 2021 Tagged CAR-T, MM

How can CAR T-cell therapy be used to treat multiple myeloma, and what is the latest in CAR T-cell research? Is it getting closer to being an approved treatment option? What are we learning from clinical trials? And finally, what should patients know?

Visit website
Immunotherapy Web Featured Images 72

Multiple Myeloma Roundtable: Immunotherapies & MRD Debate

Each year during the ASH Annual Meeting & Exposition, Patient Power brings together several of the world’s leading experts in multiple myeloma for a roundtable discussion of the latest myeloma research and news. Hear from three renowned experts and Patient Power co-founder Andrew Schorr as they discuss the state of multiple myeloma treatment today including advances in immunotherapy, new promising drug options, the role of minimal residual disease (MRD) testing in determining treatment paths, and other important topics including disparities in multiple myeloma care.

Visit website
Immunotherapy Web Featured Images 67

Comparing CAR-NK and CAR T-Cell Therapies

  Dec 29 2020 Tagged CAR-T, CAR-NK

How Do Chimeric Antigen Receptor (CAR) Therapies Differ? Dr. Katy Rezvani, Chief, Section of Cellular Therapy, Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center joins Patient Power Co-founder Andrew Schorr to explain the difference between the two new cell therapies and what this innovation means for ALL, CLL, and NHL patients.

Visit website
Immunotherapy Web Featured Images 76

ASH 2020 MPN Roundtable: Individualized Treatment Plans

  Dec 17 2020 Tagged MPN

What are the key takeaways in myeloproliferative neoplasm (MPN) research from ASH 2020? How have immunotherapy treatments advanced? Are there any promising new clinical trials? And finally, among so many options for MPN treatment, how can you and your care team create an individualized treatment plan that is right for you? Hear four of the world's leading MPN experts answer these questions and more with host and MPN patient advocate Ruth Fein. 

Visit website
Immunotherapy Web Featured Images 52

It’s All About the Antibodies! How mAbs work in Multiple Myeloma

"To understand how a monoclonal antibody works first you need to know what an antigen is. An antigen is a molecule that is able to generate antibodies in our immune system." - Read this review by Cindy Chmielewski on the mechanism of action (how they work) of each type of antibody.

Visit website
Immunotherapy Web Featured Images 89

A Hodgkin Lymphoma Patient Discusses the Phase I Clinical Trial that Saved Her L...

In this podcast, you will hear a fireside discussion from the 2020 IO360° Summit featuring cancer survivor and advocate, Ariella Chivil who walked the audience through her immunotherapy trial pathway alongside patient advocate, Cindy Geoghegan, who moderated the chat. 

Visit website
Immunotherapy Web Featured Images 23

Patient Perspectives on Cancer Immunotherapy at the 2020 CRI Virtual Immunothera...

  Nov 03 2020 Tagged ICI

At the 2020 CRI Virtual Immunotherapy Patient Summit, three CRI ImmunoAdvocates—cancer veterans treated with immunotherapy— share their experiences with cancer, immunotherapy, health care, and support.

Visit website